Avadel Pharmaceuticals Appoints Sev Melkonian as Vice President of Patient Services, Distribution, and Reimbursement
Avadel Pharmaceuticals (NASDAQ: AVDL) has appointed Sev Melkonian as Vice President of Patient Services, Distribution, and Reimbursement. Melkonian brings over 20 years of healthcare operations and patient services leadership experience, most recently serving at Takeda Pharmaceuticals where he led Patient Access Partner Operations.
The appointment comes as Avadel continues its search for a new Chief Commercial Officer while focusing on establishing LUMRYZ as the preferred oxybate treatment in the narcolepsy community. Melkonian's expertise includes building healthcare operations, managing patient support service teams, and navigating rare disease drug commercialization.
Melkonian's educational background includes an MBA from Northeastern University, an MHA from Suffolk University, and a BS in Pharmacy from the Massachusetts College of Pharmacy and Health Sciences. His previous experience also includes leadership roles at CVS Health's Pharmaceutical Purchasing Organization.
Avadel Pharmaceuticals (NASDAQ: AVDL) ha nominato Sev Melkonian come Vicepresidente dei Servizi per i Pazienti, Distribuzione e Rimborso. Melkonian porta con sé oltre 20 anni di esperienza nella gestione delle operazioni sanitarie e dei servizi per i pazienti, avendo recentemente lavorato presso Takeda Pharmaceuticals, dove ha diretto le Operazioni dei Partner per l’Accesso dei Pazienti.
La nomina avviene mentre Avadel continua la sua ricerca di un nuovo Direttore Commerciale, concentrandosi sull'affermazione di LUMRYZ come trattamento preferito a base di ossibato nella comunità della narcolessia. L'esperienza di Melkonian include la costruzione di operazioni sanitarie, la gestione di team di supporto ai pazienti e la navigazione nella commercializzazione di farmaci per malattie rare.
Il percorso educativo di Melkonian include un MBA presso la Northeastern University, un MHA presso la Suffolk University e una laurea in Farmacia presso il Massachusetts College of Pharmacy and Health Sciences. Il suo precedente esperienza include anche ruoli di leadership presso l'Organizzazione per l'Acquisto Farmaceutico di CVS Health.
Avadel Pharmaceuticals (NASDAQ: AVDL) ha nombrado a Sev Melkonian como Vicepresidente de Servicios para Pacientes, Distribución y Reembolso. Melkonian aporta más de 20 años de experiencia en operaciones de atención médica y liderazgo en servicios para pacientes, habiendo trabajado recientemente en Takeda Pharmaceuticals, donde lideró las Operaciones de Socios de Acceso para Pacientes.
El nombramiento se produce mientras Avadel continúa su búsqueda de un nuevo Director Comercial, enfocándose en establecer LUMRYZ como el tratamiento de oxibato preferido en la comunidad de narcolepsia. La experiencia de Melkonian incluye la construcción de operaciones de atención médica, la gestión de equipos de servicio de apoyo a pacientes y la navegación de la comercialización de medicamentos para enfermedades raras.
El historial educativo de Melkonian incluye un MBA de la Northeastern University, un MHA de la Suffolk University y una licenciatura en Farmacia del Massachusetts College of Pharmacy and Health Sciences. Su experiencia previa también incluye roles de liderazgo en la Organización de Compras Farmacéuticas de CVS Health.
아바델 제약 (NASDAQ: AVDL)은 세브 멜코니안을 환자 서비스, 유통, 및 환급 담당 부사장으로 임명했습니다. 멜코니안은 20년 이상의 의료 운영 및 환자 서비스 리더십 경험을 보유하고 있으며, 최근에는 타케다 제약에서 환자 접근 파트너 운영을 이끌었습니다.
이번 임명은 아바델이 새로운 상업 이사를 찾고 있는 가운데 LUMRYZ를 기면증 커뮤니티에서 선호되는 옥시베이트 치료제로 자리 매김하는 데 주력하고 있다는 점에서 이루어졌습니다. 멜코니안은 의료 운영 구축, 환자 지원 서비스 팀 관리 및 희귀질환 의약품 상용화 관리에 대한 전문성을 가지고 있습니다.
멜코니안의 교육 배경에는 노스이스턴 대학교의 MBA, 서폭 대학교의 MHA, 메사추세츠 약대 및 건강 과학 대학의 약학 학사 학위가 포함됩니다. 그의 이전 경험에는 CVS 헬스의 제약 구매 조직에서의 리더십 역할도 포함됩니다.
Avadel Pharmaceuticals (NASDAQ: AVDL) a nommé Sev Melkonian Vice-Président des Services aux Patients, Distribution et Remboursement. Melkonian apporte plus de 20 ans d'expérience en opérations de santé et en leadership des services aux patients, ayant récemment travaillé chez Takeda Pharmaceuticals où il a dirigé les opérations des partenaires d'accès pour les patients.
Cette nomination survient alors qu'Avadel poursuit sa recherche d'un nouveau Directeur Commercial, tout en se concentrant sur l'établissement de LUMRYZ comme le traitement à base d'oxybate préféré dans la communauté de la narcolepsie. L'expertise de Melkonian comprend la construction d'opérations de santé, la gestion des équipes de soutien aux patients et la navigation dans la commercialisation des médicaments pour les maladies rares.
Le parcours éducatif de Melkonian comprend un MBA de la Northeastern University, un MHA de la Suffolk University et un BS en pharmacie du Massachusetts College of Pharmacy and Health Sciences. Son expérience précédente comprend également des rôles de leadership au sein de l'Organisation d'Achats Pharmaceutiques de CVS Health.
Avadel Pharmaceuticals (NASDAQ: AVDL) hat Sev Melkonian zum Vizepräsidenten für Patientendienste, Verteilung und Erstattung ernannt. Melkonian bringt über 20 Jahre Erfahrung in der Gesundheits- und Patientenserviceleitung mit, zuletzt war er bei Takeda Pharmaceuticals tätig, wo er die Patient Access Partner Operations leitete.
Die Ernennung erfolgt, während Avadel weiterhin nach einem neuen Chief Commercial Officer sucht und sich darauf konzentriert, LUMRYZ als bevorzugte Oxybat-Behandlung in der Narcolepsie-Community zu etablieren. Melkonians Expertise umfasst den Aufbau von Gesundheitsoperationen, das Management von Patientensupport-Serviceteams und die Kommerzialisierung von Arzneimitteln für seltene Krankheiten.
Melkonians Ausbildungshintergrund umfasst einen MBA von der Northeastern University, einen MHA von der Suffolk University und einen BS in Pharmazie vom Massachusetts College of Pharmacy and Health Sciences. Zu seinen früheren Erfahrungen gehören auch Führungspositionen in der Pharmaceutical Purchasing Organization von CVS Health.
- Strategic hire with extensive experience in rare disease patient services and drug commercialization
- Strengthens commercial leadership during CCO transition period
- Brings valuable expertise in patient access and support services for LUMRYZ commercialization
- Currently operating without a Chief Commercial Officer
DUBLIN, Ireland, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that Sev Melkonian has joined the company as Vice President of Patient Services, Distribution, and Reimbursement. Mr. Melkonian has extensive industry experience building and leading healthcare operations and patient support service teams across global healthcare and biopharmaceutical organizations.
"We are thrilled to welcome Sev to the Avadel team," said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals. "Providing comprehensive support to patients and providers and continuously improving their experience with LUMRYZ is critical to Avadel’s success. Sev’s expertise in establishing and leading patient access centers of excellence while navigating the complexities of commercializing new drugs in the rare disease space makes him uniquely qualified to accelerate LUMRYZ’s adoption as the preferred oxybate for patients and providers. His background and skillset will be invaluable as we search to replace our Chief Commercial Officer and, in parallel, continue establishing LUMRYZ’s leadership within the narcolepsy community."
Mr. Melkonian brings more than 20 years of healthcare operations and patient services leadership to Avadel. Most recently, he led Patient Access Partner Operations at Takeda Pharmaceuticals, where he directed teams in support of Takeda’s USBU Portfolio including Rare Disease Patient Services Programs. Prior to joining Takeda Pharmaceuticals, Mr. Melkonian held leadership roles within CVS Health's Pharmaceutical Purchasing Organization in the areas of Pharmaceutical Trade, Distribution and Drug Pricing. Mr. Melkonian holds an MBA from Northeastern University, an MHA from Suffolk University, and a BS in Pharmacy from the Massachusetts College of Pharmacy and Health Sciences.
“Joining Avadel at this juncture offers an exciting opportunity to build on its strong patient support foundation as the Company enters its next phase of commercial launch,” said Mr. Melkonian. “I look forward to helping narcolepsy patients and providers and optimizing their experience with LUMRYZ.”
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZTM, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or EDS in patients 7 years of age and older with narcolepsy. For more information, please visit www.avadel.com.
Investor Contact:
Austin Murtagh
Precision AQ
Austin.Murtagh@precisionaq.com
(212) 698-8696
Media Contact:
Lesley Stanley
Real Chemistry
lestanley@realchemistry.com
(609) 273-3162
FAQ
Who is the new Vice President of Patient Services at Avadel Pharmaceuticals (AVDL)?
What is Sev Melkonian's experience prior to joining AVDL?
How will Melkonian's appointment impact LUMRYZ's commercialization for AVDL?
What key positions is Avadel Pharmaceuticals (AVDL) currently seeking to fill?
